Unknown PHASE1 INTERVENTIONAL 2-arm NCT03808701

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer (sNSCLC)

Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Advanced Squamous Non-small Cell Lung Cancer : a Phase Ib, Open-label, Multicenter Study

Sponsor: Sinocelltech Ltd.

Conditions Advanced Squamous Non-small Cell Lung Cancer

Interventions SCT200

Updated 5 times since 2019 Last updated: Jan 16, 2019 Started: Mar 31, 2019 Primary completion: Dec 31, 2019 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Squamous Non-small Cell Lung Cancer and is currently ongoing. Sinocelltech Ltd. leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Feb 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE1
Feb 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinocelltech Ltd.

Data source: Sinocelltech Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.